Afluria Quadrivalent Influenza Vaccine Description
Afluria Quadrivalent is an inactivated egg-based influenza vaccine that is designed to protect against four different flu viruses, including two influenza A viruses and two influenza B viruses.
For 2020-2021, quadrivalent (four-component) egg-based vaccines are recommended to contain:
- A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus (updated)
- A/Hong Kong/2671/2019 (H3N2)-like virus (updated)
- B/Washington/02/2019 (B/Victoria lineage)-like virus (updated)
- B/Phuket/3073/2013-like (Yamagata lineage) virus
Afluria Quadrivalent Influenza Vaccine Indication
Afluria Quadrivalent is indicated in people 6 months of age and older, for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Afluria Quadrivalent Influenza Vaccine Dosage
Afluria is administered as an intramuscular injection by needle and syringe (6 months and older) or by PharmaJet®Stratis® Needle-Free Injection System (18 through 64 years).
Afluria Quadrivalent Influenza Vaccine News
July 30, 2020 - Seqirus Begins Shipping 2020/21 Influenza Vaccines to the U.S. Market